Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 2, 2020
Daily News
April 2, 2020
- PMDA Introduces 3 New Consultation Services
April 2, 2020
- PMDA Issues Q&A for Trial Implementations in Coronavirus Crisis
April 2, 2020
- Keidanren Calls for Review of Health Coverage for OTC-Like Drugs
April 2, 2020
- Eisai, Seikagaku Pair Up for Osteoarthritis Drug in China
April 2, 2020
- Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
April 2, 2020
- Japan’s Healthcare Would Collapse before “Overshoot,” Govt Panel Warns
April 2, 2020
- Japan Ruling Parties Call for Fund to Support Healthcare Delivery System
April 2, 2020
- Pfizer Pausing Global Trial Recruitments, but Not in Japan
April 2, 2020
- Daiichi Sankyo Gets License to Ultragenyx’s Gene Therapy Manufacturing Techs
April 2, 2020
- Adcetris plus Chemo Gets EU Panel OK for Front-Line Use: Takeda
April 2, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
- Chugai Maps Out Digital Vision for 2030 Aiming at Value Chain Optimization, Novel Drug Discovery
April 2, 2020
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…